{
  "author": {
    "name": "Beckie Fenrick",
    "webUrl": "/author/profile/beckie-fenrick/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 2,
    "social": [],
    "articles": [
      {
        "uri": "/2023/07/21/the-cost-implications-of-new-weight-loss-treatments-for-plan-sponsors/",
        "title": "The cost implications of new weight loss treatments for plan sponsors",
        "byline": "Beckie Fenrick",
        "kicker": "Market Insights",
        "prettyDate": "July 21, 2023",
        "timeToRead": "7 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/09/Obese.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/beckie-fenrick/",
            "name": "Beckie Fenrick"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "Could drugs in the latest generation of medications approved to promote weight loss be a solution?",
        "body": null
      },
      {
        "uri": "/2023/04/10/humira-biosimilars-are-finally-here-what-brokers-and-tpas-need-to-know/",
        "title": "Humira biosimilars are finally here: What brokers and TPAs need to know",
        "byline": "Beckie Fenrick and Brian Shonat",
        "kicker": "Market Insights",
        "prettyDate": "April 10, 2023",
        "timeToRead": "5 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2022/04/Medical-Pills-Article-202204131136.jpg",
          "width": "620",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/beckie-fenrick/",
            "name": "Beckie Fenrick"
          },
          {
            "webUrl": "/author/profile/brian-shonat/",
            "name": "Brian Shonat"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "Employers, brokers and TPAs need to calibrate their expectations for how Humira biosimilars will impact the cost of prescription drugs for groups and members.",
        "body": null
      }
    ]
  }
}